


0800-1730 **XXXI Annual Meeting of the Sociedad Chilena de Urología**

ROOM: Doña Inés

 *English-Spanish and Spanish-English Translation Provided*

0800-0820 **Registration**

0820-0830 **Welcome and Opening Remarks**

Gustavo Salgado
President, Sociedad Chilena de Urología

0830-0900 **Evolution of Pharmacotherapy for BPH**

Mostafa Elhilali, Canada

0900-0910 **Questions**

0910-0940 **A New Paradigm for Male Lower Urinary Symptoms**

Paul Abrams, UK

0940-0950 **Questions**

0950-1020 **Coffee Break**

1020-1050 **Evidence-Based Choices for Stress Urinary Incontinence Procedure**

Paul Abrams, UK

1050-1100 **Questions**

1100-1130 **Laser Prostatectomy: Where Are We in 2008?**

Mostafa Elhilali, Canada

1130-1140 **Questions**

1140-1300 **General Meeting of the SCHU**

(Restricted to active and honorary members of the SCHU)

1140-1300 **Special Session for Residents: Prostatic Biopsy and Modern TURBT**

ROOM: Don Alberto 1

 *English-Spanish Translation Provided*

Chair: Robert Donohue, USA

1300-1400 **Lunch Break**

1300-1400 **Sponsored Symposium: BACSA-ONCURA Brachytherapy for Localized Prostate Cancer**

ROOM: Don Alberto 5

Chair: Reynaldo Gómez, Chile

1300-1305 **Introduction**
Reynaldo Gómez, Chile

1305-1320 **Principles and Technique of Prostate Brachytherapy**
Felipe Balbontín, Chile

1320-1345 **Clinical Experience and Results**
Octavio Castillo, Chile

1345-1400 **Discussion Panel**
Octavio Castillo, Chile
Andrés Córdova, Chile
Felipe Balbontín, Chile

1400-1715 **Nursing Programme** *(in Spanish)*

ROOM: Don Edmundo

- 1400-1415 **Inauguración**
- 1415-1445 **Láser Verde**
Marianett Hernández
EU Pabellón Clínica Indisa
- 1445-1515 **Cistitis Intersticial**
Eleonore Schwarze
EU Hospital FACH
- 1515-1545 **Dolor**
Mirta Mur
EU Unidad del Dolor
Hospital UC
- 1545-1615 **Cambios Psicológicos y Fisiológicos del Adulto Mayor**
Georgina Gómez
EU Dipl. en Geriatría
- 1615-1645 **Risoterapia**
Ramona Norambuena
EU Hospital Sotero del Río
- 1645-1715 **Enfermería en Cirugía Mínimamente Invasiva**
Paula Espinoza, EU Urología Clínica
Santa María

1400-1730 **Free Paper Sessions**

Session 1: Podium and Moderated Posters

ROOM: Doña Inés

 *English-Spanish Translation Provided*

PART 1

Chairs: Norman Zambrano, Chile
Luis Ebel, Chile

Podium

- 1400-1410 **VEGF165b, an Inhibitory Splice Variant of VEGF165 in Transitional Cell Carcinoma of the Bladder: In Vivo Expression**
SCHU-01
Shyamala Gopi, UK
- 1410-1420 **The Roles of Steroid Hormones in Female Bladder Outlet Obstruction Patients and Rat Model**
SCHU-02
Zhou-Jun Shen, China
- 1420-1430 **Novel Biomarkers in Prostate Cancer Detection**
SCHU-03
Emmanuel Johnson, UK

Moderated Posters

- 1430-1435
SCHU-04 **Radical Retropubic or Perineal Prostatectomy Worsens the Quality of Life of Cancer Patients at Six Month Follow-up**
Homero De Arruda, Brazil
- 1435-1440
SCHU-05 **Neuroanatomical Study of Periprostatic Nerve Distributions Using Human Cadaver Prostates**
Kyung-Sik Han, South Korea
- 1440-1445
SCHU-06 **Neuroendocrine Carcinoma of the Prostate: A Poor Prognosis?**
Octavio Castillo, Chile
- 1445-1450
SCHU-07 **Is Routine Prostate Biopsy a Reliable Predictor of Laterality and Pathological Features in Early Stage, Low-Risk Prostate Cancer**
Alfredo Domenech, Chile
- 1450-1455
SCHU-08 **Prognostic Factors in the Transrectal Prostate Ultrasound-Guided Biopsy in Radical Prostatectomy Patients**
Cristián Acevedo, Chile
- 1455-1500
SCHU-09 **Benign Prostatic Hyperplasia and Prostatic Cancer Aminopeptidasis**
Sonia Oliveira-Montanaro, Brazil

PART 2

Chairs: Cristián Trucco, Chile
Rodrigo Riveri, Chile

Moderated Posters

- 1500-1505
SCHU-10 **Influence of Body Mass Index on Serum PSA Concentration in Prostate Cancer Screening**
José Daniel López Laur, Argentina
- 1505-1510
SCHU-11 **Laprosopic Radical Cystectomy in Muscle Invasive Bladder Cancer: A Single Centre Experience**
Mahesh Desai, India

1510-1515
SCHU-12

Laprosopic Radical Nephrectomy Versus Open Radical Nephrectomy: A Contemporary Outcome Analysis
Mahesh Desai, India

1515-1520
SCHU-13

Percutaneous Radiofrequency Ablation (RFA) of Renal Tumours
Emmanuel Johnson, UK

1520-1525
SCHU-14

High Intensity Focused Ultrasound Renal Tissue Ablation: A Laparoscopic Porcine Model
Marcelo Orvieto, USA

1525-1530
SCHU-15

Our Experience with Laparoscopic Partial Nephrectomy
Christian Ramos, Chile

1530-1535
SCHU-16

Retroperitoneoscopic Surgery for Adrenal Microlesions: Our Experiences
Zhou-Jun Shen, China

1535-1540
SCHU-17

Retroperitoneal Laparoscopic Radical Nephrectomy: Our Initial Experience
Vladimir Moraga Lalanne, Chile

1540-1545
SCHU-18

Embryonal Rhabdomyosarcoma of the Urachus Presenting as Acute Abdomen: A Case Report
Ana María Castillo Fernández, Chile

1545-1550
SCHU-19

Result of a Conservative Conduct in Pyeloureteral Tumors
Rubén Guillermo Bengío, Argentina

1550-1555
SCHU-20

E-Cadherin Predictive Value for Recurrence of Bladder Non-invasive Tumors (TA -T1)
Rubén Guillermo Bengío, Argentina

1555-1600
SCHU-21

Uroflowmetry Alterations in Women with Stress Urinary Incontinence
José Flores, Chile

1600-1605
SCHU-22

Urethral Stricture: Our Experience
Octavio Castillo, Chile

1605-1610
SCHU-23

Ostomy Problems with Catheterizable Continent Reservoirs

Gabriel Catalán, Chile

1610-1615
SCHU-24

Sex-Related Differences in Gene Expression in Pre-pubertal and Pubertal Mouse Bladder

Yanlan Yu, China

1615-1620
SCHU-25

Complication Rate of Suburethral Tape Techniques in the Treatment of Stress Incontinence

Pedro Edgardo Rivera, Chile

1620-1625
SCHU-26

Tubeless Percutaneous Renal Surgery in Supine Position: Initial Experience

Benjamín Silva, Chile

1625-1630
SCHU-27

Transurethral Bulking Agent Injection: Promissory Results Using the New 'Vantris' Macroparticle in the Treatment of Stress Urinary Incontinence

Tomás Olmedo, Chile

1630-1635
SCHU-28

Pheocromocytoma in Children: Is Laparoscopic Adrenalectomy Safe?

Francisco Tibor Dénes, Brazil

1635-1640
SCHU-29

Notch-3 and Notch-4 in the Development of a Normal Prostate Gland in a Mouse

Eric Milla, Chile

1640-1730

Extraordinary Presentation to the SchU on the Appointment of Dr. Rubén Olivares:

Laparoscopic Retroperitoneal Lymph Node Dissection in Testicular Cancer Clinical Stage I Nonseminomatous Germ Cell Carcinoma

Rubén Olivares, Chile

Session 2: Podium Session

ROOM: Don Alberto 4

PART 1

Chairs: Tomás Olmedo, Chile
Marcelo Silva, Chile

1400-1410
SCHU-30

Prognostic Factors for Survival After Radical Nephroureterectomy in Upper Tract Urothelial Carcinoma: Analysis of a Large Hispanic Multicentric Series

Mario Fernández, Chile

1410-1420
SCHU-31

Percutaneous Renal Surgery in Valdivia Uria Position: Our Experience in 70 Cases

Benjamín Silva, Chile

1420-1430
SCHU-32

Pathological Features of Solid Renal Tumors Measuring Less Than 4 cm

Gonzalo Rubio, Chile

1430-1440
SCHU-33

Efficacy of the Argon Beam Coagulator Alone in Obtaining Hemostasis After Laparoscopic Porcine Heminephrectomy: A Pilot Study

Marcelo Orvieto, USA

1440-1450
SCHU-34

Comparison of Clinical Factors, Surgical Complications, Functional Results and Quality of Life Between Four Different Urinary Diversions

Mario Arturo Navarro Genta, Chile

1450-1500
SCHU-35

Complications Related to Use of Intestinal Mechanic Sutures for Urinary Procedures

Pablo Marchetti, Chile

1500-1510
SCHU-36

Open vs. Laparoscopic Enterocystoplasty

Pablo Marchetti, Chile

1510-1520
SCHU-37 **Decreased Mortality in Testicular Cancer: Survival Analysis in Two Chilean Medical Centers**
Claudio Parra Díaz, Chile

1520-1530
SCHU-38 **Endourological Management of Ureteroenteric Strictures**
Octavio Castillo, Chile

1530-1540
SCHU-39 **Use of a Stent for Lower Ureteral Stones in Ureterscopy: A Prospective Randomized Study**
Pedro Acuña Gajardo, Chile

PART 2

Chairs: René Henriquez, Chile
Orosmán Canales, Chile

1540-1550
SCHU-40 **Continent Reconstructive Surgery of The Neurogenic Bladder**
Reynaldo Gómez, Chile

1550-1600
SCHU-41 **Complications in Percutaneous Nephrolithotomy: A Comparative Study Between Supine and Prone Position Using the Modified Clavien System**
Alfredo Domenech, Chile

1600-1610
SCHU-42 **Demucosed Colocystoplasty Preserving the Urothelium: Our Experience**
Esteban Arias Orellana, Chile

1610-1620
SCHU-43 **Treatment of Non-metastatic Rhabdomyosarcoma of the Prostate in Childhood and Adolescence: The Role of Surgery**
Juan Carlos López, Argentina

1620-1630
SCHU-44 **Changes in Urinary Symptoms Following I-125 Prostate Brachytherapy**
Pablo Pizzi, Chile

1630-1640
SCHU-45 **Photoselective Vaporization of the Prostate: Analysis of a Series with More Than One Year of Follow-Up**
Christian Ramos, Chile

1640-1650
SCHU-46 **Laser Vaporization Versus Prostate Transurethral Resection for the Treatment of Prostatic Hyperplasia: Comparison of Their Clinical Effectiveness**
Tomás Olmedo, Chile

1650-1700
SCHU-47 **A Retrospective Study of 80 Patients with Organ-Confined Prostate Cancer Treated with Brachytherapy**
Felipe Balbontín, Chile

1700-1710
SCHU-48 **Impact of Body Mass Index in Patients Undergoing Transrectal Biopsy for Prostate Cancer Screening**
Cristián Acevedo, Chile

1710-1720
SCHU-49 **Electrochemical Ablation of the Prostate: A Feasibility Study for the Treatment of Prostate Cancer and Benign Prostatic Hyperplasia**
Juan Cabezas, Chile

Session 3: Moderated Videos

ROOM: Don Alberto 3

Chairs: Felipe Balbontín, Chile
Marcelo Kerkebe, Chile

1400-1420
SCHU-50 **Antegrade Endopyelotomy in Supine Position for Ureteropelvic Junction Obstruction in an HIV(+) Patient**

Benjamín Silva, Chile

1420-1440
SCHU-51 **Percutaneous Nephrolitotomy in Supine Position with a Dilator Balloon**

Benjamín Silva, Chile

1440-1500
SCHU-52 **Laparoscopic Resection of Bladder Tumor: Combined Endoscopic and Laparoscopic Approach**

Hugo Bermúdez, Chile

1600 **Exhibit Open**

ROOM: Don Bernardo

1800-1900 **SIU Opening Ceremonies**

ROOM: Doña Inés

1900-2100 **SIU Welcome Reception**

ROOM: Don Bernardo

0700-0800 **National Delegates' Meeting and Breakfast**

ROOM: Don Edmundo

0800-0830 **Welcome Plenary**

ROOM: Doña Inés

 *English-Spanish Translation Provided*

0800-0805 **Scientific Committee Welcome**

Richard D. Williams, USA
Laurence Klotz, Canada

0805-0830 **To Treat the Patient or To Operate Only? That Is the Question of Urologic Oncology**

Joachim Thüroff, Germany
With contributions from
Michael Droller, USA
Laurence Klotz, Canada
Paul Lange, USA

0830-1100 **Plenary: Testis Cancer**

ROOM: Doña Inés

 *English-Spanish Translation Provided*

Chairs: Octavio Castillo, Chile
Joel Sheinfeld, USA

0830-0840 **New Developments in Testis Cancer**

Joel Sheinfeld, USA

0840-0850 **Imaging of Testicular Cancer**

Kristen Bouchelouche, Denmark

0850-0900 **Update on Testicular Tumor Pathology**

Jonathan Epstein, USA

0900-0915 **Biochemical/Genetic Markers of Testis Cancer**

Alfredo Velasco, Chile

0915-0930 **Small Testicular Mass Management-Biopsy/Total vs. Partial Orchiectomy**

Osvaldo Mazza, Argentina

0930-1010 **Panel: Post-orchietomy Stage I Non-seminomatous Testicular Cancer Management**

Moderator: Michael Jewett, Canada

0930-0940 **Watchful Waiting/Active Surveillance: Indications and Outcome**

Michael Jewett, Canada

0940-0950 **Primary Chemotherapy**

Jorge Gutiérrez, Chile

0950-1000 **Primary RPLND, Indications and Methods**

Octavio Castillo, Chile

1000-1010 **Discussion**

1010-1050 **Point-Counterpoint: Post-chemotherapy Management**

Moderator: Richard D. Williams, USA

1010-1025 **Surgery**

Joel Sheinfeld, USA

1025-1040 **Conservative**

Jerome Richie, USA

1040-1050 **Discussion**

1050-1100 **Testis Cancer Follow-Up Methods**

Octavio Castillo, Chile

1100-1115 **Coffee Break**

1115-1305 **Podium and Moderated Poster Sessions**

1115-1305 **Podium Session**

POD-1 – Minimally Invasive Surgery

ROOM: Don Alberto 5

Chair: René Sotelo, Venezuela

1115-1125 **Trifecta Outcomes in Preoperatively Potent Men After Nerve Sparing Robotic Laparoscopic Radical Prostatectomy**

POD-1.01
Marcelo Orvieto, USA

1125-1135 **The Impact of Warm Ischemia Time on Perioperative Outcomes and Creatinine Clearance in Patients Undergoing Laparoscopic Partial Nephrectomy**

POD-1.02
Marcelo Orvieto, USA

1135-1145 **The Adjustable Male Sling for Stress Urinary Incontinence After Prostate Surgery**

POD-1.03
Barthold Philip Schrier, Netherlands

1145-1155 **RFA and Cryoablation as Treatment for Small Renal Tumours: A Literature Study with Analysis of Complications and Short-Term Results**

POD-1.04
Carl Van Haute, Belgium

1155-1205 **Laparoscopic Adrenalectomy in Children: A Safe and Effective Procedure**

POD-1.05
Pablo Lobos, Argentina

1205-1215 **Laparoscopic Adrenalectomy for Malignant Adrenal Masses**

POD-1.06
Rodrigo Campos, Chile

1215-1225 **International Multi-Center Evaluation of the Adjustable Continence Therapy (Proact™) for Male Post-prostatectomy Stress Urinary Incontinence**

POD-1.07
Flavio Trigo Rocha, Brazil

1225-1235 **Suprapubic Cystostomy at Time of Vattikuti Institute Prostatectomy (VIP): Preliminary Results with Catheter Removal on Postoperative Day 1**

POD-1.08
Louis Spencer Krane, USA

1235-1245 **Advantages of Hand-Assisted Laparoscopic Partial Nephrectomy**

POD-1.09
Chris Teigland, USA

1245-1255 **Radiofrequency Ablation of Small Renal Masses: A Multicenter Analysis of Intermediate Term Results of 56 Tumors in 49 Patients**

POD-1.10
Steven Joniau, Belgium

1255-1305 **Maximizing Console Surgeon Independence During Robotic Kidney Surgery by Utilizing the 4th Arm and TilePro**

POD-1.11
Louis Spencer Krane, USA

1115-1305 Podium Session

POD-2 – Penile and Testis Cancer

ROOM: Don Alberto 3

Chairs: Arturo Mendoza-Valdés, Mexico
Alberto Bustamante, Chile

1115-1125 **Partial and Total Penectomy for Patients with Squamous Cell Carcinoma of the Penis: A Single Institute Experience**

POD-2.01

Yuvaraja Thyavihally, India

1125-1135 **Management of Germ Cell Tumors in Undescended Testis: A Single Institute Series**

POD-2.02

Yuvaraja Thyavihally, India

1135-1145 **Penile Cancer: Results From 380 Cases Treated by Surgery**

POD-2.03

Apostolos Rempelakos, Greece

1145-1155 **Diagnosis of Human Papillomavirus (HPV): Infection of Male Genital Skin and Mucosa**

POD-2.04

Slawomir Dutkiewicz, Poland

1155-1205 **Preservation of Erectile Function After Penile Cancer Radical Surgery**

POD-2.05

Edoardo Austoni, Italy

1205-1215 **Organ-Preserving Surgery for Penile Cancer**

POD-2.06

Steven Joniau, Belgium

1215-1225 **Methylation in Testicular Cancer**

POD-2.07

Ivar Vidal, Chile

1225-1235 **Chemotherapy for Testis Conservation in Patients with Germ Cell Cancer (GCC): Is It Safe and Could Combination with Tumour Enucleation Increase the Frequency of Success?**

POD-2.08

Tim Oliver, UK

1235-1245 **Long-Term Follow-Up in Patients with Non-germinal Testicular Tumors**

POD-2.09

Alejandro Foneron, Chile

1245-1255 **Incidence of Retroperitoneal Teratoma in Patients with Non-seminomatous Germ Cell Cancer of the Testis**

POD-2.10

Javier Dominguez, Chile

1255-1305 **Brachytherapy for Squamous Carcinoma of the Penis: A Penile Conserving Option**

POD-2.11

Juanita Crook, Canada

1115-1230 Moderated Poster Session

MP-1 – Prostate Cancer, Growth Factors Advanced Disease Management

ROOM: Don Alberto 1

Chairs: Peter Ekman, Sweden
Carlos Giudice, Jr., Argentina

MP-1.01 **The Role of Hyperinsulinemia and Insulin Resistance in Prostate Growth: Are They Truly Associated with Prostatic Enlargement?**

MP-1.01

Young Hoon Lee, South Korea

MP-1.02 **CD133, Ki-67 and AR Cell Marker in the Mouse Prostate Gland During Development and Growth**

MP-1.02

Carlos Sánchez, Chile

- MP-1.03 **The Minisatellites Polymorphisms within hTERT Gene Region with Cancer Predisposition**
Seil Jung, South Korea
- MP-1.04 **Aqueous Extract of *Phellinus linteus* Induces Apoptosis in Human DU-145 Prostate Cancer Cells**
Han Jung, South Korea
- MP-1.05 **Prognostic Value of Growth Factors Production in Prostate Cancer Patients**
Boris Alekseev, Russia
- MP-1.06 **Is Diabetes Mellitus Associated with Aggressive Characteristics in Prostate Cancer?**
Louis Spencer Krane, USA
- MP-1.07 **Association Between Toll-like Receptor 4 Polymorphisms and Prostate Cancer in Korean Men**
Gilho Lee, South Korea
- MP-1.08 **Multicenter Phase III Randomized Controlled Trial of Toremifene to Prevent Fractures and Other Adverse Effects of Androgen Deprivation Therapy in Men with Prostate Cancer**
Mitchell Steiner, USA
This presentation was supported by an unrestricted educational grant from GTX, Inc.
- MP-1.09 **Metabolic Changes in Androgen Deprivation Therapy for Prostate Cancer: Chlormadinone Acetate May Have a Favorable Effect on Lipid Metabolism**
Hideki Sakai, Japan
- MP-1.10 **Salvage Radiotherapy After Open Radical Retropubic Prostatectomy: Our 14 Year Experience**
Richard Cetti, UK

- MP-1.11 **Functional and Oncological Outcome of Locally-Advanced Prostate Cancer Primarily Treated by Radical Prostatectomy**
Alexander Hinev, Bulgaria
- MP-1.12 **Circulating LDH Value in HRPc Patients After Ten Cycles of Chemotherapy: A Marker of Soft Tissue Lesions**
Marko Tarle, Croatia
- MP-1.13 **Sub-Epididymal Orchidectomy for Metastatic Prostate Carcinoma: A Point of Technique**
Shivadeo Bapat, India
- MP-1.14 **Expression of HER-2 in Disseminated Tumor Cells in Bone Marrow of Patients with Prostate Cancer Is Associated with Resistance to Androgen Blockage but not DES**
Leonardo Badinez, Chile
- MP-1.15 **Predictive Factors for Failing to Achieve a Nadir Prostate Specific Antigen of 1.0ng/ml or Less After Combined Androgen Blockade**
Seung Chol Park, South Korea
- MP-1.16 **HER2 Protein: Is It a Potential Predictor of Locally-Advanced Prostate Carcinoma?**
Ljupco Lekovski, Macedonia

1230-1345 **Lunch, Exhibits**

ROOM: Don Bernardo

1230-1345 **Poster Viewing**

ROOM: Galería Doña Elvira

1345-1540 **Plenary: Kidney Cancer**

ROOM: Doña Inés

 *English-Spanish Translation Provided*

Chairs: Simon Tanguay, Canada
Norman Zambrano, Chile

1345-1355 **New Developments in Kidney Cancer**

Simon Tanguay, Canada
*This presentation was supported
by an unrestricted educational grant
from Pfizer*

1355-1405 **Imaging of Renal Cancer**

Manuel Fernández, Chile

1405-1415 **Update on Renal Mass Pathology**

Jonathan Epstein, USA

1415-1430 **Biochemical/Genetic Markers of Kidney Cancer**

TBC

1430-1520 **Panel: Management of 3-4 cm Renal Mass**

Moderator: Michael Marberger, Austria

1430-1440 **Indications/Methods/Complications for Renal Mass Biopsy**

Steven Campbell, USA

1440-1450 **Surveillance**

Alessandro Volpe, Italy

1450-1500 **Indications and Outcomes for Partial Nephrectomy**

Richard Santucci, USA

1500-1510 **Ablative Therapies**

Michael Marberger, Austria

1510-1520 **Discussion**

1520-1530 **Integration of New Systemic Therapies Into the Urologic Practice: An Overview**

Chris Wood, USA

1530-1540 **Kidney Cancer Follow-Up Methods**

Norman Zambrano, Chile

*This presentation was supported
by an unrestricted educational grant
from Pfizer*

1540-1600 **Coffee Break**

1530-1830 **The Society of GU Reconstructive Surgeons (GURS)**

ROOM: Don Alberto 4

Reconstructive Procedures After GU Cancer Therapy

Moderator: Allen F. Morey, USA

Session 1 – General Considerations: Effects of Aging on Outcomes

1530-1545 **Reconstructive Surgery in Geriatric Patients**

Tomas L. Griebling, USA

Session 2 – Anastomotic Complications

Co-Moderator: Michael J. Metro, USA

1545-1600 **Incidence**

Sean P. Elliott, USA

1600-1615 **Endoscopic Treatment of Bladder Neck Contracture**

Christopher M. Gonzalez, USA

1615-1630 **Urolume Stent and Open Reanastomosis**

Jack W. McAninch, USA

1630-1645 **Discussion and Questions**

Session 3 – Challenges in Incontinence

Co-Moderator: Brian J. Flynn, USA

1645-1700 **AdVance Sling**

Kurt McCammon, USA

1700-1715 **Reoperative and Transcorporal AUS**

Kenneth W. Angermeier, USA

1715-1730 **Discussion and Questions**

Session 4 – Rectourethral Fistulas

Co-Moderator: Reynaldo Gómez, Chile

1730-1750 **Rectourethral Fistulas**

Daniel J. Culkín, USA

1750-1830 **Panel Discussion/Case Presentations**

Co-Moderator: Steven B. Brandes, USA

Panelists: Gerald H. Jordan, USA
Jack W. McAninch, USA
Kenneth W. Angermeier, USA
Daniel J. Culkín, USA

1600-1800 **Surgical Tips**

ST-1 – Testis Cancer

ROOM: Don Alberto 3

Chair: Octavio Castillo, Chile

Faculty: Joel Sheinfeld, USA
Jerome Richie, USA
Michael Jewett, Canada
Marcelo Rosa Travassos, Brazil

ST-2 – Kidney Cancer

ROOM: Doña Inés

Chair: Michael Marberger, Austria

Faculty: Steven Campbell, USA
Simon Tanguay, Canada
Hein Van Poppel, Belgium

1600-1800 **Moderated Poster Sessions**

MP-2 – Bladder Cancer

ROOM: Don Alberto 1

Chairs: Serigne Gueye, Senegal
Mario Gorena, Chile

MP-2.01 **Surgical Apgar: Perioperative Risk Assessment for Radical Cystectomy**

Marcos Dias Ferreira, Brazil

MP-2.02 **Identification of Novel MicroRNA Targets Based on MicroRNA Signature in Bladder Cancer**

Hideki Enokida, Japan

MP-2.03 **Continent Orthotopic Sigmoid Neobladder Urinary Diversion After Radical Cystectomy: Evolution of Technique and Long-Term Data**

Ismail Khalaf, Egypt

MP-2.04 **Broadhesive Coated Nanoparticles Loaded with Mitomycin C for the Effective Chemotherapy of Superficial Bladder Cancer**

N. Aydin Mungan, Turkey

MP-2.05 **Pathologic Pattern of Invasive Bladder Carcinoma: Impact of Bilharziasis**

Ismail Khalaf, Egypt

- MP-2.06 **Cytokine Levels in Patients of Transitional Cell Carcinoma Urinary Bladder**
Amlesh Seth, India
- MP-2.07 **The Antiproliferative Activity of MCC (Mycobacterial Cell Wall-DNA Complex) Is Independent of p53 Mutational Status, p21 Gene Polymorphisms, Aneuploidy of Chromosomes 3, 7 and 17, and Loss of 9p21 Locus in Bladder Cancer Cell Lines**
Mario C. Filion, Canada
- MP-2.08 **Anti-tumor Effect on Bladder Cancer with Conditionally Replicating Oncolytic Viruses Derived from Herpes Simplex Viruses**
Young Sam Cho, South Korea
- MP-2.09 **Detection of Circulating Tumor Cells in the Blood of Patients with Muscle Invasive Bladder Cancer Prior to Radical Cystectomy**
Thomas Guzzo USA
- MP-2.10 **Identification of Aberrant Promoter Methylation of TBX5, PENK and T in Detection of Urothelial Carcinoma in Exfoliated Urine Cells**
Chong Koo Sul, South Korea
- MP-2.11 **Prognostic Significance of Cyclooxygenase-2 (COX-2) Immunoreactivity in Inflammatory Stromal Cells in COX-2 Positive Urothelial Bladder Tumors**
Ivica Mokos, Croatia
- MP-2.12 **Transurethral Layer-Section of Muscle Invasive Bladder Cancer: Accurate T Staging and Bladder Preservation in a Selected T2 Bladder Cancer**
WT Kim, South Korea
- MP-2.13 **The Efficacy of Urine Cytology, Nuclear Matrix Protein (NMP) 22 Fluorescence In Situ Hybridization (FISH) in Bladder Cancer**
WT Kim, South Korea
- MP-2.14 **Underlying Malignancy Is the Most Common Cause of Urinary Retention in Women in a Developing African Country**
Chris Van Der Walt, South Africa
- MP-2.15 **Long-Term Outcomes of Sigmoid Neobladder After Radical Cystectomy in an Indian Population: A Single Centre Experience**
Amlesh Seth, India
- MP-2.16 **Clinical Outcome Following Prostatic Capsule and Seminal Sparing Cystectomy for Bladder Cancer in 25 Men**
Andreas Thorstenson, Sweden
- MP-2.17 **Feasibility Study of Population-Based Screening for Bladder Cancer with Urinary Molecular Markers (BLUP): (www.blu-project.org)**
Monique J. Roobol, Netherlands
- MP-2.18 **Detection Rate of Malignancy in Patients with Lower Urinary Tract Symptoms Without Pyuria**
Tong Choon Park, South Korea
- MP-2.19 **Is Seminal Sparing Vesicle Possible in Radical Cystectomy of Organ-Confining Bladder Cancer?**
Mario Arturo Navarro Genta, Chile
- MP-2.20 **Impact of Repeat Transurethral Resection on Recurrence of Primary Non-muscle Invasive Bladder Cancer**
Roman Tomaskin, Slovakia

MP-2.21 **BCG Intravesical Therapy in Bladder Tumor: 6 Week Course Versus Modified 6+3 Maintenance Therapy**

Jae Il Chung, South Korea

MP-2.22 **Low Recurrence Rate of Superficial Bladder Cancer: Is Re-Resection Necessary in Our Patients?**

Javier Domínguez, Chile

MP-2.23 **Side Effects and Complications of Intravesical BCG Instillation in the Treatment of Non-muscle Invasive Bladder Cancer**

Mártha Orsolya, Romania

MP-2.24 **Bladder Cancer Incidence and Mortality Among Workers Exposed to Benzidine and 3,3-Dichlorobenzidine**

Mark Schoenberg, USA

MP-2.25 **Initial Experience with Hexvix-Induced Fluorescence Blue Light Cystoscopy in Bladder Cancer Diagnosis**

Petrisor Geavlete, Romania

MP-2.26 **Urinary NMP22 BladderChek Test in Diagnosis of Bladder Cancer and Comparison with Urinary Cytology and Cystoscopic Biopsy**

Pramod Kumar Sharma, India

MP-2.27 **Differences in Tumor Characteristics and Prognosis According to the Age in Patients with Newly Diagnosed Ta, T1 Transitional Cell Carcinoma of the Bladder**

Dong Suk Kim, South Korea

1600-1800 **Moderated Poster Session**

MP-3 – Prostate Cancer, Localized Disease

ROOM: Don Alberto 2

Chairs: Muhammad Bulbul, Lebanon
Felipe Balbontín, Chile

MP-3.01 **Learning Curve Improves Functional and Oncological Outcomes on Pure Laparoscopic Prostatectomy: Experience of a Reference Center in Brazil**

Marcos Tobias-Machado, Brazil

MP-3.02 **Manual or Robotic High Intensity Focused Ultrasound (HIFU) in Prostate Cancer Therapy**

Stefan Thueroff, Germany

MP-3.03 **Transurethral Adenoma Resection Before High Intensity Focused Ultrasound (HIFU) Treatment of Prostate Cancer**

Stefan Thueroff, Germany

MP-3.04 **Robotic Assisted Surgical Management of High-Risk Prostate Cancer**

John Davis, USA

MP-3.05 **Hypofractionated Accelerated Radiotherapy for Low-Risk Localized Prostate Cancer: The Further Follow-Up of a Weekly Canadian Regimen**

Andrew Loblaw, Canada

MP-3.06 **Impact of Pelvic Lymph Node Dissection in High-Risk Prostate Cancer**

Alexander Hinev, Bulgaria

- MP-3.07 **Clinical Experience with HIFU in Patients with Low-Risk Primary Prostate Cancer**
George Suarez, USA
- MP-3.08 **Quality of Life After HIFU Treatment for Localized Prostate Cancer**
Pavel Shestiperov, Russia
- MP-3.09 **Robotic Radical Prostatectomy in Morbidly Obese Patients**
Louis Spencer Krane, USA
- MP-3.10 **Perioperative and Pathological Outcomes in Obese Men: An Analysis of the Robotic Assisted Laparoscopic Radical Prostatectomy**
Marcos Dias Ferreira, Brazil
- MP-3.11 **Pathological Gleason Score Trends in Patients Undergoing Radical Prostatectomy**
Marcelo Orvieto, USA
- MP-3.12 **Brachytherapy After 12 Years: Our Experience with 412 Cases with a Minimum Follow Up of 12 Months**
Marcelo Borghi, Argentina
- MP-3.13 **Extraperitoneal Laparoscopic Radical Prostatectomy: Results of a Learning Curve After 310 Cases**
Octavio Castillo, Chile
- MP-3.14 **Visually Directed High Intensity Focused Ultrasound: Techniques to Reduce Urethral Strictures**
Stephen Scionti, USA
- MP-3.15 **Patterns of Care for Radical Prostatectomy in the United States from 2003-2005**
Marcos Dias Ferreira, Brazil

- MP-3.16 **Impact of Prostate Weight on Surgical Outcomes of Robotic Assisted Laparoscopic Radical Prostatectomy**
Marcos Dias Ferreira, Brazil
- MP-3.17 **Prostate Size Is Associated with Surgical Difficulty but not Functional Outcome at One Year**
Farhang Rabbani, USA
- MP-3.18 **Robotic Prostatectomy in Patients Over Seventy Years**
Louis Spencer Krane, USA
- MP-3.19 **Results of Extended and Radioisotope-Guided Pelvic Lymph Node Dissection in Prostate Cancer Patients**
Boris Alekseev, Russia
- MP-3.20 **Outcomes of High Intensity Focused UltraSound (HIFU) in the Treatment of Localized Prostate Cancer**
Roberto Sanseverino, Italy
- MP-3.21 **Total Reconstruction: Technique for Precision Anastomosis and Continence Preservation**
Gerald Tan, USA
- MP-3.22 **Gleason 6 Prostate Cancer in 1 or 2 Biopsy Cores Can Harbor More Aggressive Disease**
Marcelo Orvieto, USA

2000-2300 **Optional Evening,
An Evening at the Races**

Club Hípico Santiago

*Tickets may be purchased in the Registration area.
Transportation from Congress hotels will be provided.
Business elegant attire.*

Unmoderated Posters

ROOM: Galería Doña Elvira

On display from Thursday, November 20 to Saturday, November 22

- UP.01 **Comparison of 18FDG PET/CT and MRI for N-staging of Urothelial Bladder Cancer: Correlation with Histopathologic Findings**
Thor Knak Jensen, Denmark
- UP.02 **Laparoscopic Surgery of Primary Renal Lymphoma: A Difficult Case**
Sorayya Tavasoli Yousefabad, Iran
- UP.03 **Cystoscopically-Guided Transurethral Incision of the Bladder Neck by Nd:YAG Laser in Vesicourethral Stricture After Prostatectomy**
Mohamad Reza Razaghi, Iran
- UP.04 **Retroperitoneal Lymph Node Dissection in Post-chemotherapy Residual Masses in Testicular Germ Cell Tumors in an Indian Population: A Single Centre Experience**
Amllesh Seth, India
- UP.05 **Laparoscopic Post-chemotherapy Retroperitoneal Resection of Residual Masses in Germ Cell Tumor Patients: Our Experience**
Fernando Cabrera, Spain
- UP.06 **Efficacy and Safety of Active Surveillance for Testicular Cancer**
Alfred Krebs, Chile
- UP.07 **20-year Phase 1/2 Study of Single Agent Carboplatin in Metastatic Seminoma: Could it Have Been Accelerated by 72 hr PET Scan Response?**
Tim Oliver, UK

- UP.08 **Detection of Renal Disease in a Population Investigated for Microscopic Haematuria**
Angela Cottrell, UK
- UP.09 **Extra Adrenal Pheochromocytoma of Urinary Bladder: A Case Report and Review of Literature**
Pramod Kumar Sharma, India
- UP.10 **Mineralocorticoid Expression Is a Negative Prognostic Predictor in Patients with Renal Cell Carcinoma**
Tetsuo Ogushi, Japan
- UP.11 **Renal Cell Carcinoma: Atypical Clinical Manifestation**
Aleksandar Ilievski, Macedonia
- UP.12 **Renal Cell Carcinoma, Sarcomatoid Variant: Our Experience of 10 Years at the Clinical Hospital of the University of Chile**
Miguel Angel Cuevas, Chile
- UP.13 **Renal Cell Carcinoma with Sarcoid-like Stromal Reaction**
Alvaro Ibarra, Chile
- UP.14 **Malignant Renal Mesenchymoma**
Alvaro Ibarra, Chile
- UP.15 **Short- and Long-Term Surgical Outcomes of Laparoscopic Radical Nephrectomy for Kidney Cancer: A Single Center Experience in Brazil**
Marcos Tobias-Machado, Brazil
- UP.16 **Nephron-Sparing Surgery for Renal Tumors: Laparoscopic-Assisted Radio Frequency Ablation with Curative Intent**
Ivar Vidal, Chile

- UP.17 **A Distinctive Translocation Carcinoma of the Kidney ('Rosette Forming', t(6;11), HMB45 positive)**
Milan Hora, Czech Republic
- UP.18 **Burden of Bone Metastases from Renal Cell Carcinoma: Zoledronic Acid and Functional Independence**
Lawrence Drudge-Coates, UK
- UP.19 **Spontaneous Rupture of Renal Tumors**
Sabah Alkadhi, Qatar
- UP.20 **Green Light (532 nm) Laser Partial Nephrectomy Followed by the Suture of the Collecting System Without Renal Hilar Clamping in a Porcine Model**
Viktor Eret, Czech Republic
- UP.21 **Seminal Vesicle Carcinoma: 4 Clinical Cases Reported from the Clinical Hospital of University of Chile between 1990-2005**
Miguel Angel Cuevas, Chile
- UP.22 **Bowen's Disease of the Penis: Clinical Hospital, University of Chile Experience**
Miguel Angel Cuevas, Chile
- UP.25 **Do Androgen Receptor Polymorphisms Contribute to an Increased Risk for Benign Prostate Hyperplasia (BPH)?**
Ki Hak Song, South Korea
- UP.26 **Metastatic Infiltration of the Ureter: Leading Cause of Ureteral Obstruction in Patients Who Died from Ovarian Carcinoma**
Gernot Bonkat, Switzerland
- UP.27 **Korean Red Ginseng Reduces Ischemia/Reperfusion-Induced Bladder Oxidant Stress and Dysfunction in Rats**
Chong Koo Sul, South Korea
- UP.28 **The Breakdown of Regeneration Among People of Older Age Groups and Carcinogenesis**
Alexander Pechersky, Russia
- UP.29 **Effect of Nutritional Status on Baseline Intraresidual Pressure and Clinical Significance**
Aníbal Salazar, Chile
- UP.30 **Nutrition Profile and Bone Loss in Prostate Cancer Patients Receiving Long-Term Androgen Deprivation**
Marcos Tobias-Machado, Brazil
- UP.31 **Robotic Assisted Radical Prostatectomy in the Renal Allograft Recipient**
Gerald Tan, USA
- UP.32 **Robotic Radical Prostatectomy Utilizing a Custom-Made Synchronous Suprapubic Vesical Urinary Diversion Device and Anastomotic Splint: Report of Initial Series and Perioperative Outcomes**
Gerald Tan, USA
- UP.33 **Return of Orgasmic Function in Patients Undergoing Robotic Prostatectomy**
Gerald Tan, USA

- UP.34 **A Comparative Head-on Efficacy Study of 3 Monthly Goserelin 10.8 mg, 3 Monthly Leuprolide 11.25 mg and 3 Monthly Leuprolide 22.5 mg with 6 Monthly Leuprolide 45mg Preparations for Treatment in Patients with Prostate Cancer**
Rajeev Sood, India
- UP.35 **HIFU in Prostate Cancer Treatment**
Pavel Shestiperov, Russia
- UP.37 **Outcome of Radical Prostatectomy According to Pathological Gleason Score**
Andrés Figueroa, Chile
- UP.38 **Should Extended Core Biopsy Be a Rule for the Detection of Prostate Cancer in Gray Zone PSA?**
Chang-Ho Lee, South Korea
- UP.39 **The Incidence of High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) in TRUSG-Guided Prostate Biopsy Specimens: Data of the Referred Patient Population from a High-Volume Community Training Hospital**
Ahmet Bölükbası, Turkey
- UP.40 **The Importance of Biopsy Protocol in Terms of Correct Gleason Grading of Patients Prior to Radical Prostatectomy: Preliminary Results**
Ahmet Bölükbası, Turkey
- UP.41 **The Association of Increased Number of Positive Prostate Biopsy Cores with Gleason Grade Upstaging Following Radical Prostatectomy**
Ahmet Bölükbası, Turkey
- UP.42 **Correlation of Pre-operative Prostate Specific Antigen (PSA) with Gleason Grading in Prostate Cancer Diagnosis**
Christian Kofi Gyasi-Sarpong, Ghana
- UP.43 **Comparison of the Oncologic Outcome Between Retropubic and Laparoscopic Radical Prostatectomy**
Oscar Storme, Chile
- UP.44 **Comparison of Surgical Outcome: Urinary Continence and Sexual Function Between Laparoscopic and Retropubic Radical Prostatectomy**
Oscar Storme, Chile
- UP.45 **Role and Significance of Neo-Adjuvant Hormonal Therapy on Patients Undergoing Vattikuti Institute Robotic Radical Prostatectomy (RRP): A Case-Matched Comparative Study**
Louis Spencer Krane, USA
- UP.46 **Mini TURP for Obstructed Patients Prior to Prostate Brachytherapy (PB)**
Marcelo Borghi, Argentina
- UP.47 **Primary Carcinoma of Seminal Vesicles: Role of Surgery in Presence of Metastasis: Case Report**
Octavio Castillo, Chile
- UP.49 **Value of Complex PSA Percentage to Define Prostate Cancer Aggressiveness in Patients with Total PSA Between 2.5 and 10ng/dl**
Anton Zarraonandia, Spain
- UP.50 **Low Dose Brachytherapy to Treat Prostate Cancer: Oncological Results**
Anton Zarraonandia, Spain

- UP.51 **The Impact of Obesity on Laparoscopic Radical Prostatectomy**
Fernando Cabrera, Spain
- UP.52 **Prostate Cancer and Sexual Function after External Beam Radiotherapy, with the Use of a Cytoprotective Agent (Amifostine): The Efficacy of Sildenafil**
Emmanouil Patris, Greece
- UP.53 **Are There Any Differences Between Symptomatic Prostate Cancers and Asymptomatic Screened Prostate Cancers?**
Chang-Ho Lee, South Korea
- UP.54 **The Multidisciplinary Uro-Oncology Team: Auditing Outcomes**
Priyadarshi Kumar, UK
- UP.55 **PSA and Retention: To Do or Not to Do?**
Priyadarshi Kumar, UK
- UP.56 **Holmium Laser as a Treatment for Anastomotic Stricture Following Radical Prostatectomy**
Priyadarshi Kumar, UK
- UP.57 **Possible Role of Vertebral Veins in the Dissemination of Prostate Cancer: Cluster Analysis of Metastatic Patterns to the Skeletal Systems with Bone Scintigrams**
Toru Onita, Japan
- UP.58 **Prognostic Factor of Early Dissemination of Radically Treated Prostate Cancer Patients**
Hubert Urbanczyk, Poland
- UP.59 **Quality-of-Life Outcomes in Patients Undergoing Emerging Techniques for the Treatment of Localised Prostate Cancer: A Prospective Study**
Ruban Thanigasalam, Australia
- UP.60 **Issues Faced in the Transition from Open to Robot-Assisted Laparoscopic Radical Prostatectomy in the Contemporary Era**
Ruban Thanigasalam, Australia
- UP.61 **Does Every Patient with High PSA (>100ng/ml) Need Prostate Biopsy?**
Young-Sig Kim, South Korea
- UP.62 **Advanced Robotic Assisted Laparoscopic Prostatectomy Training: Building the Foundation of a Reproducible Operation**
John Davis, USA
- UP.63 **Widespread Indications for Radical Prostatectomy: Does it Make Sense?**
Jasenko Djozic, Serbia
- UP.64 **The Effects of Naftopidil on Lower Urinary Tract Symptoms After Radical Prostatectomy**
Kazuhiro Ishizaka, Japan
- UP.65 **The Study of Repeat Prostate Biopsy for Undetected Prostate Cancer**
Young-Joo Kim, South Korea
- UP.66 **Sexual Rehabilitation After Radical Retropubic Prostatectomy (RRP): Results of a Clinical Study on 40 Patients Treated with Tadalafil and Alprostadil**
Tommaso Brancato, Italy

- UP.67 **Sexual Function and Prognostic Factors for Post-implant Urinary Retention After Prostate Brachytherapy**
Apostolos Rempelakos, Greece
- UP.68 **Prostate Cancer Review: Komfo Anokye Teaching Hospital, Ghana**
Christian Kofi Gyasi-Sarpong, Ghana
- UP.69 **Polymorphism of CYP1A1 MSP1 and Mortality in Patients with Prostatic Cancer: Seven-Year Follow-Up**
Juan Fullá, Chile
- UP.70 **Patients with a Single Microfocus (<5%) of Gleason 6 Prostate Cancer at Biopsy: Can We Predict Adverse Pathological Outcomes?**
Marcelo Orvieto, USA
- UP.71 **Lack of Stimulation of Histamine Release by Ozarelix, a 4th Generation GnRH Antagonist on Human Basophils**
Bela Denes, USA
- UP.72 **A Comparison of the Pharmacokinetics of Ozarelix: A Novel GnRH Antagonist, Administered IM vs. SC**
Bela Denes, USA
- UP.73 **Initial Experience with HIFU in Patients with Prostate Cancer**
Marcelo Borghi, Argentina
- UP.74 **Magnetic Resonance Spectrometry in Prostate Cancer Diagnosis**
Alfredo Velasco, Chile
- UP.75 **Intra- and Peri-operative Outcomes Comparing Radical Retropubic and Laparoscopic Radical Prostatectomy: Our Experience**
Gemma Isabel Duque, Spain
- UP.76 **Impact of Total Anatomic Reconstruction of the Bladder Neck in Obese Men: Continence Outcomes Following Robotic Prostatectomy**
Gerald Tan, USA
- UP.77 **Prostate Cancer Diagnosed at Multiple Repeat Biopsies Following Isolated High-Grade Prostatic Intraepithelial Neoplasia: Which Cancers are Significant at Radical Prostatectomy Specimen?**
Steven Joniau, Belgium
- UP.78 **DD3/PCA3 (Differential Display Code 3) in Prostate Cancer Diagnosis: Experience from Czech Republic**
Jiri Klecka, Czech Republic
- UP.79 **Detection of Prostate Cancer: A Comparative Study of the Diagnostic Value of Transrectal Biopsy Using a Standard Versus an End-Curved Biopsy Needle: About 100 Cases**
Sataa Sallami, Tunisia
- UP.80 **Influence of Weight Loss on Serum Prostate Specific Antigen Levels in Patients who Undergo Bariatric Surgery**
José Antonio Salvadó, Chile
- UP.81 **Early Prostate Cancer Recurrence Prediction Following HIFU Treatment Using AMACR and PSA Immunohistochemical Evaluation**
Pavel Shestiperov, Russia
- UP.82 **Expression of p50 and p65 Proteins in the Development and Growth of the Prostatic Gland of Mice: Animal Model**
German Venegas, Chile

- UP.83 **P0 Stage at Radical Cystectomy for Bladder Cancer: What Is the Outcome? Are There Any Clinical Risk Factors? Our 7 Cases**
Sataa Sallami, Tunisia
- UP.84 **A Comparison of the Outcomes of Ileal and Sigmoid Orthotopic Neobladders in the Management of Invasive Bladder Carcinoma**
S. Yavuz Önal, Turkey
- UP.85 **Expression and Correlation of Cyclooxygenase-2, Angiogenin and Vascular Endothelial Growth Factor in Human Transitional Cell Carcinoma**
Hyung-Lae Lee, South Korea
- UP.86 **Our Experience of Holmium Laser for Recurrent Papillary Tumors of the Bladder**
Shivadeo Bapat, India
- UP.87 **Bladder Cancer and the Aluminum Industry: A Review of the Current Literature**
Thomas Guzzo, USA
- UP.88 **Preliminary Experience with Video-Assisted Radical Cystectomy: Perioperative Parameters Compared with Open Conventional Procedure**
Marcos Tobias-Machado, Brazil
- UP.89 **Concomitant Carcinoma In Situ in Patients with Superficial Bladder Tumors**
Petrisor Geavlete, Romania
- UP.90 **Clinical Outcome of Primary Conservative Treatment for High Grade Non-muscle Invasive Bladder Cancer**
Mario Fernández, Chile
- UP.91 **Total Pelvic Exenteration for Colorectal Cancer: A Review of General and Genitourinary Outcomes**
Trustin Domes, Canada
- UP.92 **Orthotopic Neobladder with Prostatic Cone Preservation**
Alejandro Foneron, Chile
- UP.93 **Prognostic Value of Re-TURB of High-Risk Non-invasive Bladder Cancer**
Roberto Sanseverino, Italy
- UP.94 **Salvage Cystectomy Indications in Bladder Cancer**
Oleksandr Stakhovskiy, Ukraine
- UP.95 **Orthotopic New Bladder Urethral Diversion After 10-16 Years of Radical Cystectomy and Ileal Conduit**
Mohamed Wishahi, Egypt
- UP.96 **Bladder Substitution with Orthotopic Ileal Neobladder in Organ Confined Bladder Cancer: Results of 2 Surgical Techniques**
Mario Arturo Navarro Genta, Chile
- UP.97 **Ten-Year Experience of Urethral Cancer**
Angela Cottrell, UK
- UP.98 **Quality of Life and Voiding Function Following Neobladder Formation**
Angela Cottrell, UK
- UP.99 **The Peri-meatus Location of Superficial Bladder Transitional Cell Carcinoma (T1): Is It a Risk Factor of Recurrence and Progression? Our 278 Cases**
Sataa Sallami, Tunisia
- UP.100 **Transutricular Seminal Vesiculoscopy: Technical Considerations and Outcomes**
Seung-Choul Yang, South Korea

0800-1600 **World Pediatric Uro-Oncology Update Section: Clinical Cases**
This session is concurrent with the SIU Uro-Oncology programme.

ROOM: Don Alberto 4

Chairs: Francisco de Badiola, Argentina
 Pedro-José López, Chile

0800-0830 **Registration**

0830-0840 **Welcome**

Francisco de Badiola, Argentina
 Pedro-José López, Chile

0840-1000 **Clinical Cases in Pediatric Urology**

1000-1030 **Coffee Break**

1030-1230 **Clinical Cases in Pediatric Uro-Oncology**

1230-1345 **Lunch**

1345-1445 **Investigation Protocols in Pediatric Uro-Oncology: Current and Future Status**

Marcio Malogolowkin, USA

1445-1600 **Free Papers in Pediatric Urology**

Chairs: Francisco de Badiola, Argentina
 Pedro-José López, Chile

PED-01 **Recovery Factors Affecting Discard of Small Pediatric Donor Kidneys**

Shiro Fujita, Japan

PED-02 **Does Renal Scarring Affect the Spontaneous Resolution and Breakthrough Infection in Children with Vesicoureteral Reflux (VUR)?**

Jae-Shin Park, South Korea

PED-03 **Long-Term Functional Results of Continent Ileocecal Urinary Reservoir in Exstrophy-Epispadias Complex**

Ibrahim Bassiouny, Qatar

PED-04 **Sutureless Circumcision**
 Seyed Aladdin Asgari, Iran

PED-05 **Endoscopic Urethral Anastomosis to Disrupted Bladder After Pelvic Fracture in Children**
 Mohamed Wishahi, Egypt

PED-06 **Screening for Uro-Genital Congenital Malformations**
 Vasile Dan Stanca, Romania

PED-07 **Demucosed Colocystoplasty Preserving the Urothelium: Our Experience**
 Esteban Arias Orellana, Chile

0800-1100 **Plenary: Prostate Cancer**

ROOM: Doña Inés

 *English-Spanish Translation Provided*

Chairs: Laurence Klotz, Canada
 Christian Ramos, Chile

0800-0810 **New Developments in Prostate Cancer**
 Laurence Klotz, Canada

0810-0820 **Imaging of Prostate Cancer**
 Kristen Bouchelouche, Denmark

0820-0835 **New Prostate Cancer Markers**
 Yves Fradet, Canada

0835-0850 **Prostate Cancer Pathology-Perspective on Early Lesions**
 Jonathan Epstein, USA

0850-0930 **Panel: Does Prostate Cancer Screening Reduce Mortality?**
Moderator: Arturo Mendoza Valdés
Mexico

0850-0905 **ERSPC Study**
Fritz Schroeder, Netherlands

0905-0920 **PLCO Study**
Gerald Andriole, USA

0920-0930 **Discussion**

0930-0945 **Prevention and Nutritional Management of Prostate Cancer**
Neil Fleshner, Canada

0945-1035 **Panel: Primary Treatment Outcomes for Intermediate-Risk, PSA 10-20, Gleason 7**
Moderator: Eric Klein, USA

0945-0955 **Radiotherapy/Brachytherapy**
Andrés Córdova, Chile

0955-1005 **Radical Prostatectomy**
Eric Klein, USA

1005-1025 **Ultrasound and MP-Guided HIFU: Update**
Laurence Klotz, Canada

1025-1035 **Discussion**

1035-1050 **Hormone-Resistant Prostate Cancer: New Treatments**
Atif Akdas, Turkey

1050-1100 **Prostate Cancer Follow-Up Methods**
Christian Ramos, Chile

1100-1115 **Coffee Break**

1115-1230 **Podium and Moderated Poster Sessions**

1115-1230 **Podium Session
POD-3 – Prostate Cancer,
Advanced Disease**

ROOM: Don Alberto 3

Chairs: Robert Nam, Canada
Camilo Sandoval Herrera, Chile

1115-1125
POD-3.01 **Intermittent Androgen Suppression Delayed the Time to PSA Failure in Locally-Advanced and Metastatic Prostate Cancer Compared with Continuous Androgen Suppression in Japan**
Naohide Sato, Japan

1125-1135
POD-3.02 **Outcome of Patients with Positive Surgical Margins Following Radical Prostatectomy Treated with Adjuvant Hormonal and Radiation vs. Salvage Therapy: Selection Criteria Identified**
Muhammad Bulbul, Lebanon

1135-1145
POD-3.03 **Evaluation of a New Incisionless Technique for Surgical Androgen Deprivation in Men with Prostate Cancer: A Prospective Randomized Comparison of Bilateral Orchiectomy and Clamp Ablation of the Testes**
Chris F. Heyns, South Africa

1145-1155
POD-3.04 **Early Salvage Radiotherapy After Radical Prostatectomy at a Low PSA Level**
Ladislav Jarolim, Czech Republic

1155-1205
POD-3.05

N-Telopeptide of Type I Collagen (NTX) Response to Zoledronic Acid in Patients with Bone Metastases from Prostate Cancer

Fred Saad, Canada

1205-1215
POD-3.06

How Frequent are Metabolic Syndrome and Cardiovascular Risk Factors in Patients Receiving Long-Term Hormonal Therapy for Prostate Cancer Treatment?

Marcos Tobias-Machado, Brazil

1215-1225
POD-3.07

An Open-Label, Phase II Trial of 250mg Gefitinib (Iressa) in Prostate Cancer Patients with Early Biochemical Failure Post-prostatectomy

Laurence Klotz, Canada

1115-1230 **Moderated Poster Session**

MP-4 – Prostate Cancer, Localized Disease

ROOM: Don Alberto 1

Chairs: Michael Hehir, UK
Luis Martínez Venegas, Chile

MP-4.01

Ablatherm HIFU in Organ-Confined Prostate Cancer: A Single Centre Canadian Experience

William Orovan, Canada

MP-4.02

Prostate Cancer in Patients with PSA Values Between 2.5-4.0 ng/ml: Predictive Value of PSA Velocity

Petrisor Geavlete, Romania

MP-4.03

P504S Expressing Prostate Cells in Blood of Healthy Men: A Possible Screening Test for Prostate Cancer

Nigel P. Murray, Chile

MP-4.04

Results in Patients with PSA of 2.5-4ng/ml and 4-10ng/ml Candidates for Prostate Biopsy

Anton Zarraonandia, Spain

MP-4.05

Comparison of Robotic-Assisted Versus Retropubic Radical Prostatectomy Performed by a Single Surgeon

Yen-Chuan Ou, Taiwan

MP-4.06

Do the Epstein Criteria Continue to Predict Insignificant Prostate Cancer in the Modern Day Urological Setting?

Ruban Thanigasalam, Australia

MP-4.07

Outcomes of Repeated Prostatic Biopsy Following HGPIN and ASAP on Initial Biopsy

Roberto Sanseverino, Italy

MP-4.08

Value of DRE and PSA for Early Detection of Prostate Cancer During Prostate Awareness Campaign: Nationwide Study in Egypt

Ismail Khalaf, Egypt

MP-4.09

TargetScan®: A Novel Approach for Outpatient Prostate Biopsy with the Potential for Use as an Aid to Focal Prostate Therapy

James K. Bennett, USA

MP-4.10

Pathological Characteristics of Prostate Adenocarcinomas Associated with High-Grade Prostatic Intraepithelial Neoplasia (HGPIN)

Ahmet Bölükbaşı, Turkey

MP-4.11 **Men with Prostate Cancer and Histological Evidence of Prostatitis Present with Acute Urinary Retention at an Earlier Stage of the Disease Compared to Those Without Prostatitis**

Christiaan Van Der Walt, South Africa

MP-4.12 **Prevalence of Lower Urinary Tract Symptoms (LUTS) in Men with Adenocarcinoma of the Prostate, and Prospective Randomized Evaluation of the Alpha-adrenergic Blocker Doxazosin for the Treatment of LUTS in Men with Prostate Cancer**

Joggie Stander, South Africa

MP-4.13 **Apical Periprostatic Nerve Blockade Before Transrectal Ultrasound-Guided Prostate Biopsy: Are There Any Failure Factors? Our 254 Patients**

Sataa Sallami, Tunisia

MP-4.14 **Evaluation of Two Prostate Cancer Risk Calculators in a Clinical Setting**

Vítor Cavadas, Portugal

MP-4.15 **Active Surveillance in Patients with Low Risk Prostate Cancer Using a 20-core Saturation Biopsy Technique**

Ignacio San Francisco, Chile

MP-4.16 **Real-Time Tissue Imaging of Prostate and Periprostatic Neural Tissue with Multiphoton Microscopy**

Gerald Tan, USA

MP-4.17 **Prostate Cancer Is Significant Even in Low PSA Ranges with a Family History**

Louis Spencer Krane, USA

MP-4.18 **Novel Use of 3-Tesla Magnetic Resonance Microscopy in Staging Early Prostate Cancer: Congruency Between Radiologic Anatomy and Final Histopathology**

Gerald Tan, USA

MP-4.19 **Impact of Intraoperative Biopsies During Nerve-Sparing Radical Prostatectomy**

Elmar Heinrich, Germany

1115-1230 **Moderated Poster Session**

MP-5 – Kidney and Ureteral Cancer/ Renal Pelvis

ROOM: Don Alberto 2

Chair: Mahesh Desai, India

MP-5.01 **Correlation of Histopathological Features to Tumor Size Among Patients with T1a Renal Tumors**

Joseph Chin, Canada

MP-5.02 **Prognostic Value of Lymphatic Vessel Density and Lymphangiogenesis in Upper Tract Urothelial Carcinoma**

Mario Fernández, Chile

MP-5.03 **A Retrospective Study of Implications on Survival of Histopathological Subtyping and Nuclear Grading of Renal Cell Carcinoma**

Young-Joo Kim, South Korea

MP-5.04 **Proteomic Analysis for Human Renal Cell Carcinoma Cell Clones Having Different Metastatic Potentials**

Yasuhiro Kuramitsu, Japan

- MP-5.05 **Significance of Sonoscopically Evaluated Parameters Predicting Malignant vs. Benign Renal Mass on Percutaneous Biopsy**
Edmundas Starolis, Lithuania
- MP-5.06 **Clinical Follow-Up Study of Brain Metastasis of Renal Cell Carcinoma**
Hyun Yul Rhew, South Korea
- MP-5.07 **Is the Mass Size Important in Decision-Making for Nephron Sparing Surgery?**
Sinasi Yavuz ÖnoI, Turkey
- MP-5.08 **Analysis of Survival and Prognostic Factor of Renal Cell Carcinoma with Bone Metastasis**
Hyun Yul Rhew, South Korea
- MP-5.09 **The Role of Lymphadenectomy in the Surgical Management of Renal Cell Carcinoma**
Ljupco Lekovski, Macedonia
- MP-5.10 **Troublesome Points in Renal Angiomyolipoma**
Kikyung Kim, South Korea
- MP-5.11 **Increased Nuclear Factor-Kappa B Activation and Its Prognostic Significance in Human Upper Urinary Tract Transitional Cell Carcinoma**
Hsin-Chih Yeh, Taiwan
- MP-5.12 **Conventional Renal-Cell Carcinomas in Patients with Radiation Exposure Following the Chernobyl Accident: Comparison with Spanish Cases**
Alina Romanenko, Ukraine
- MP-5.13 **Nephron-Sparing Surgery for Renal Tumor in Allograft Kidney**
Anton Zarraonandia, Spain
- MP-5.14 **Renal Cell Carcinoma with Macroscopic Level I Tumor Thrombus Extension in to the Renal Vein: Our 7-Case Experience**
Octavio Castillo, Chile
- MP-5.15 **Laparoscopic Nephroureterectomy for Upper Tract Transitional Cell Carcinoma: Results from a Single Center Experience**
Octavio Castillo, Chile
- MP-5.16 **Outcome of Cystic Renal Cell Carcinoma as Compared with Solid Tumors**
Alfredo Velasco, Chile
- MP-5.17 **Long-term Follow-up of Laparoscopic Radical Nephrectomy for Organ-Confined Renal Cell Carcinoma: Comparison with Open Radical Nephrectomy**
Sung Joon Hong, South Korea
- MP-5.18 **A Multidisciplinary Approach to the Management of Small Renal Tumors**
Chris Teigland, USA
- MP-5.20 **Growth Factor Expression in the Renal Cell Carcinoma (RCC) and Their Relationship with Classical Prognostic Factors**
Mario Domínguez Esteban, Spain
- MP-5.21 **Over-Expression of HER-2 Is a Prognostic Factor in Upper Tract Urothelial Carcinoma Post-radical Nephroureterectomy**
Wei-Ming Li, Taiwan

1230-1345 **Lunch, Exhibits**

ROOM: Don Bernardo

1230-1345 **Poster Viewing**

ROOM: Galería Doña Elvira

1230-1345 **Sponsored Symposium**

ROOM: Don Alberto 5

Sponsored by sanofi-aventis

Maximizing Clinical Efficacy of Advanced Prostate Cancer Treatment: Integrating the Specialties

1230-1235 **Introduction**

Fernando Vargas, Chile

1235-1245 **Appropriate Assessment of Patients with Advanced Prostate Cancer**

Octavio Castillo, Chile

1245-1255 **When Is the Best Time to Start Chemotherapy?**

Joachim Bellmunt, Spain

1255-1330 **Expert Practice in mHRPC – Interactive Clinical Cases:**

Chemotherapy for Patients with Minimal Pain and High-Risk Disease

Chemotherapy for Senior Adult Patients

Octavio Castillo, Chile
Osvaldo Aren, Uruguay
Joachim Bellmunt, Spain

1330-1340 **Continuing Commitment of sanofi-aventis in Urology**

Isabelle Tabah-Fisch, France

1340-1345 **Closing Remarks**

Fernando Vargas, Chile

1345-1545 **Plenary: Bladder Cancer**

ROOM: Doña Inés

 *English-Spanish Translation Provided*

Chairs: Urs Studer, Switzerland
Carlos Iturriaga, Chile

1345-1355 **New Developments in Bladder Cancer**
Mahesh Desai, India

1355-1405 **Imaging of Bladder Cancer**
Kristen Bouchelouche, Denmark

1405-1415 **Bladder Cancer Pathology-Unusual Variations**
Jonathan Epstein, USA

1415-1430 **Biomarkers of Urothelial Cancer in Urine and Serum**
Michael O'Donnell, USA

1430-1445 **Intravesical Treatment of Ta/T1/CIS Bladder Cancer**
Michael O'Donnell, USA

1445-1525 **Panel: Muscle-Invasive Bladder Cancer: Perioperative Decision Process**
Moderator: Mark Soloway, USA

1445-1455 **Adjuvant vs Neoadjuvant Chemotherapy**
Mark Soloway, USA

1455-1505 **Prostate-Sparing Cystectomy**
Laurence Klotz, Canada

1505-1515 **Extent of Node Dissection**
Urs Studer, Switzerland

1515-1525 **Discussion**

1525-1535 **Long-Term Outcomes of Bladder Substitution: Ileal Conduit Diversion vs. Orthotopic Neobladder**

Aarón Torres-García, Mexico

1535-1545 **Bladder Cancer Follow-Up Methods**

Urs Studer, Switzerland

1545-1600 **Break**

1600-1800 **Surgical Tips**

ST-3 – Prostate Cancer

ROOM: Doña Inés

Chair: Peter Ekman, Sweden
Faculty: Yves Fradet, Canada
Gerald Andriole, USA
Stefan Carlsson, Sweden
Marcus Graefen, Germany

ST-4 – Bladder Cancer

ROOM: Don Alberto 3

Chair: Bedford Waters, USA

1600-1620 **Operative Tips of Radical Cystectomy in Squamous Carcinoma (Bulky Tumors) and Use of the Sigmoid/Rectal Bladder for Diversion**

Ismail Khalaf, Egypt

1620-1640 **Nerve Sparing Cystectomy and Orthotopic Diversion**

Urs Studer, Switzerland

1640-1700 **CIS/Non-muscle Invasive Urothelial Carcinoma**

Mark Soloway, USA

1700-1720 **Use of the “Standard” Ileal Conduit**

Bedford Waters, USA

1720-1800 **Discussion**

1600-1800 **Podium, Moderated Poster and Moderated Video Sessions**

1600-1800 **Podium Session**

POD-4 – Prostate Cancer, Localized Disease

ROOM: Don Alberto 5

Chairs: Joseph Chin, Canada
Raúl Valdevenito, Chile

1600-1610 **Role of TPS, TPA and PSA in Treatment Monitoring of Prostate Carcinoma**

POD-4.01

Marc Claessens, Belgium

1610-1620 **Iodine 125 Prostate Brachytherapy: 9-Year Experience with Over 1000 Patients**

POD-4.02

Juanita Crook, Canada

1620-1630 **Complications of Radical Prostatectomy: Analysis of Predictors**

POD-4.03

Farhang Rabbani, USA

1630-1640 **A Modified Vesicourethral Anastomosis Technique in Radical Retropubic Prostatectomy and Its Impact on Continence**

POD-4.04

Sinasi Yavuz ÖnoI, Turkey

1640-1650
POD-4.05 **Patient Safety Events Associated with Open and Laparoscopic Radical Retropubic Prostatectomy**

Kristin Chrouser, USA

1660-1700
POD-4.06 **Evaluation of Cystographic Leak in Patients Undergoing Robotic Prostatectomy**

Louis Spencer Krane, USA

1700-1710
POD-4.07 **Radical Prostatectomy for PSA >20 and < 100 ng/ml**

Steven Joniau, Belgium

1710-1720
POD-4.08 **Racial Disparity Remains Associative with Advanced Prostate Cancer in Late PSA-era: An Analysis of 2784 Radical Prostatectomies After 2000**

David Albala, USA

1720-1730
POD-4.09 **Accelerated Continence Recovery After Robotic Prostatectomy Using Cornell Anatomic Reconstruction Technique: Experience of 1,018 Patients**

Gerald Tan, USA

1730-1740
POD-4.10 **Phase II Study of Treatment with 5-Alpha Reductase Inhibitors (5ARIs) in Low-Risk Prostate Cancer**

Yves Fradet, Canada

1740-1750
POD-4.11 **Extent of Lymphadenectomy and Biochemical Recurrence After Radical Prostatectomy: A Multicenter Study**

Yves Fradet, Canada

1750-1800
POD-4.12 **Stratification of Age and Gleason Grade as a Model for Selection of Optimal Candidates for Definitive Therapy of Localized Prostate Cancer**

Cary Robertson, USA

1600-1800 **Moderated Poster Session**

MP-6 Penile and Testis Cancer MIS, Miscellaneous

ROOM: Don Alberto 1

Chairs: Mariela Pow-Sang, Peru
Rodrigo Riveri-López, Chile

MP-6.01 **Circumcision: A Diagnostic and Therapeutic Procedure for Penile Lesions Due to Human Papillomavirus (HPV) Infection**

Slawomir Dutkiewicz, Poland

MP-6.02 **The Role of Neoadjuvant Chemotherapy in Advanced Lymph Node Metastasis from Carcinoma of Penis**

Yuvaraja Thyavihally, India

MP-6.03 **The University of Chicago Technique for Pelvic Lymphadenectomy During Robotic Prostatectomy: Assessing Nodal Yield, Operative Statistics, and Complications**

Marcelo Orvieto, USA

MP-6.04 **Radical Endoscopic Treatment: Center for Practical Endoscopic Training on Cadavers as the Way to Improve Skills**

Vaclav Baca, Czech Republic

MP-6.05 **Expressions of Uroplakins in a Mouse Urinary Bladder with Cyclophosphamide-Induced Cystitis**

Gilho Lee, South Korea

MP-6.06 **Laparoscopic Versus Open Radical Nephrectomy for Renal Cell Carcinoma: Comparative Data**

Yuvaraja Thyavihally, India

MP-6.07 **Transperitoneal Laparoscopic Adrenalectomy: First Experience from the Balkan Peninsula**

Zivko Popov, Macedonia

MP-6.08 **Management of Clinical Stage I NSGCT Based on Pathological Stage: Role of Laparoscopic Retroperitoneal Lymph Node Dissection (RPLND)**

Csaba Pusztai, Hungary

MP-6.09 **How Much Do We Need Experts During Laparoscopic Suturing Training?**

Steven Joniau, Belgium

MP-6.10 **Evolution of Open Versus Laparoscopic Surgery: 10 Years of Changes**

Juan Antonio Peña, Spain

MP-6.11 **Antegrade Mini-Invasive Nephroureterectomy (AMNUE - Laparoscopic Nephrectomy, Transurethral Excision of Ureterovesical Junction and Lower Abdomen Incision)**

Milan Hora, Czech Republic

MP-6.12 **Mismatch Repair Expression in Testicular Cancer Predicts Recurrence and Survival**

Ivar Vidal, Chile

MP-6.13 **Quality of Surgery: Evaluating Pathological Findings of My First 20 Laparoscopic Radical Prostatectomies Compared with My Last 20 Open Radical Prostatectomies**

Sergio Guzmán, Chile

MP-6.14 **Perioperative Safety and Outcomes in Robotic Assisted Laparoscopic Prostatectomy: A New England Experience with 332 Cases**

Marcos Dias Ferreira, Brazil

MP-6.15 **Return of Continence Following Robotic Prostatectomy: Early Results at 3 and 6 Months from a Cohort of 314 Men**

Marcos Dias Ferreira, Brazil

MP-6.16 **Extrafacial Versus Interfacial Nerve-Sparing Technique for Robotic-Assisted Radical Prostatectomy: Comparison of Functional Outcomes and Side-Specific Positive Surgical Margins Rate**

Marcelo Orvieto, USA

MP-6.17 **Video-Assisted Urinary Diversion: Minimally-Invasive Approach After Pelvic Radiation Therapy**

Marcos Tobias-Machado, Brazil

1600-1820 **VID –Moderated Videos, Miscellaneous Topics in Uro-Oncology**

ROOM: Don Alberto 2

Chairs: William Lynch, Australia
Marcelo Peisojovich, Argentina

1600-1610 **Endoscopic Approach in Benign Ureteral Tumors**

VID.01

Petrisor Geavlete, Romania

1610-1620 **Uretero-Enteric Stenosis Treated by Flexible Percutaneous Approach**

VID.02

Petrisor Geavlete, Romania

1620-1630
VID.03

Video Endoscopic Inguinal Lymphadenectomy (VEIL): Our Initial Experience

Yuvaraja Thyavihally, India

1630-1640
VID.04

Knotless Greek Bar Suture to Kidney Hemostasis and Repair: A Novel Option to Achieve Reduced Warm Ischemia Time During Laparoscopic Partial Nephrectomy

Marcos Tobias-Machado, Brazil

1640-1650
VID.05

Early Continence with Novel Restoration of Bladder Neck Anatomy During Robotic Prostatectomy

Gerald Tan, USA

1650-1700
VID.06

Laparoscopic Radical Prostatectomy: Step by Step Technique

Roberto Sanseverino, Italy

1700-1710
VID.07

Twelve Years of Experience with Transrectal High Intensity Focused Ultrasound (HIFU) at 3 MHZ as Treatment of Prostate Cancer: Hints to a Successful Treatment

Stefan Thueroff, Germany

1710-1720
VID.08

Radical Prostatectomy for Locally Advanced Prostate Cancer

Marc Claessens, Belgium

1720-1730
VID.09

Laparoscopic Surgery of Renal Tumour Interaortocava Recurrence

Juan Antonio Peña, Spain

1730-1740
VID.10

Transperitoneal Laparoscopic Partial Nephrectomy with Hilar Control and Clamping

Roberto Sanseverino, Italy

1740-1750
VID.11

Laparoscopic Radical Cystectomy

Begoña Juaneda, Spain

1750-1800
VID.12

Laparoscopic Partial Nephrectomy

Begoña Juaneda, Spain

1800-1810
VID.13

Laparoscopic Retroperitoneal Lymphadenectomy for Stage I Non-seminomatous Germ Cell Cancer: Better Results When Resecting the Same Template of Open Surgery?

Marcos Tobias-Machado, Brazil

1810-1820
VID.14

Radical and Staged Simplified Video Endoscopic Inguinal Lymphadenectomy (VEIL): Minimally Invasive Options to Achieve Reduced Morbidity in Penile Carcinoma Lymph Node Management

Marcos Tobias-Machado, Brazil

2000-2300 **Chilean Folk Evening**

Los Buenos Muchachos Restaurant

Included in registration fees. Additional tickets may be purchased in the Registration Area. Transportation from Congress hotels will be provided. Business casual attire.

0800-1015 **Plenary: Penile Cancer**

ROOM: Doña Ines

 *English-Spanish Translation Provided*

Chairs: Antonio Lima Pompeo, Brazil
Antonio Puras Báez, Puerto Rico

0800-0810 **New Developments in Penile Cancer**

Antonio Puras Báez, Puerto Rico

0810-0820 **A National Campaign for Penile Cancer Prevention: The Brazilian Experience**

Luciano Favorito, Brazil

0820-0830 **Sentinel Node: How Best to Evaluate and Manage?**

Curtis Pettaway, USA

0830-0845 **Pathology of Penile Cancer and Stage Implications**

Antonio Augusto Ornellas, Brazil

0845-0900 **Circumcision for HIV, HPV and Penile Cancer Prevention**

Ajay Nehra, USA

0900-0930 **Panel: Conservative Management of Non-invasive Lesions**

Moderator: Antonio Lima Pompeo
Brazil

0900-0910 **Laser Therapy**

Richard Santucci, USA

0910-0925 **Brachytherapy and External Radiation**

Juanita Crook, Canada

0925-0930 **Discussion**

0930-0950 **Debate: Prophylactic vs. Therapeutic Inguinal Lymph Node Dissection**

Moderator: Antonio Lima Pompeo
Brazil

0930-0937 **Prophylactic**

Badrinath Konety, USA

0937-0945 **Therapeutic**

Joel Quintero, Mexico

0945-0950 **Discussion**

0950-1005 **Multimodality Therapy for Locally Advanced Penile Cancer**

Curtis Pettaway, USA

1005-1015 **Penile Cancer Follow-Up Methods**

Stênio Zequi, Brazil

1015-1215 **Surgical Tips**

ST-5 – Penile Cancer

ROOM: Don Alberto 3

Chair: Ajay Nehra, USA

Introduction

Ajay Nehra, USA

Dynamic Sentinel Node Biopsy: Techniques Including Lymphotropic Nanoparticle-Enhanced MRI

Curtis Pettaway, USA

Prophylactic Groin Dissection: Indications, Techniques, and Long-Term Results

Badrinath Konety, USA

Surgical Techniques to Reduce Morbidity During Prophylactic Groin Dissection

Antonio Lima Pompeo, Brazil

Salvage Radical Inguinofemoral Lymphadenectomy in Patients with Extranodal Disease and/or Ulcerated Groins

Antonio Puras Báez, Puerto Rico

Surgical Cases

All

1015-1230 **Podium Sessions**

POD-5 – Prostate Cancer, Localized Disease

ROOM: Don Alberto 1

Chairs: Mostafa Elhilali, Canada
José Daniel López Laur, Argentina

1015-1025 **Seladin-1 in the Prostate: A Potential Protector Against Cancer Progression**

POD-5.01 Meng Guan, Canada

1025-1035 **Clinical Application of Chromosome 8q24 SNPs in Prostate Cancer Detection**

POD-5.02 Sanoj Punnen, Canada

1035-1045 **Hyperinsulinaemia Is a Prospective Risk Factor for Developing Prostate Cancer**

POD-5.03 Jan Hammarsten, Sweden

1045-1055 **A Prospective, Randomized Study Comparing the Vienna Nomogram to an 8-Core Standard TRUS Guided Prostate Biopsy Protocol**

POD-5.04 Johannes Stander, South Africa

1055-1105 **Prostate-Targeted Biopsy Navigated by Real-time Virtual Sonography Acquired from MRI Volume Data**

POD-5.05 Satoru Ishikawa, Japan

1105-1115 **Defining Men at Increased Future Risk of Prostate Cancer: Evidence from a Population-Based Screening Cohort**

POD-5.06 Fritz Schröder, Netherlands

1115-1125 **Radical Prostatectomy Findings in Patients Considered Potential Candidates for Active Surveillance**

POD-5.07 John Davis, USA

1125-1135 **Active Surveillance for Clinically-Localized Prostate Cancer at a High Volume Tertiary Referral Center**

POD-5.08 John Davis, USA

1135-1145 **The Effect of Inflammation in the Prostate Gland on Tissue Molecular Markers for Prostate Cancer in Arab Men**

POD-5.09 Elijah O Kehinde, Kuwait

1145-1155 **Endothelin-1 Immunostaining as a Prognostic Marker of pT3a Adenocarcinoma on Prostate Biopsies**

POD-5.10 Johann Ménard, France

1155-1205 **Predictors and Pathological Features of Prostate Cancer on Repeat Biopsy with High-Grade Prostatic Intraepithelial Neoplasia (HPIN) and/or Atypical Small Acinar Proliferation (ASAP)**

POD-5.11 Joseph Chin, Canada

1205-1215 **Pathological Disease Progression on Repeat Transrectal Biopsy in a Contemporary Active Surveillance Cohort of Prostate Cancer Patients: Looking at Disease Progression with a 5-year Follow Up**

POD-5.12 Simon Tanguay, Canada

1215-1225 **Nutritional Elements Affecting Prostate Cancer Progression of Patients on Active Surveillance**

POD-5.13 Lysanne Campeau, Canada

1225-1235
POD-5.14

A Multidimensional Scale for Assessment of Sexuality After Radical Prostatectomy for Prostate Cancer

Rabah Messaoudi, France

POD-6 – Kidney and Ureteral Cancer/ Renal Pelvis

ROOM: Don Alberto 2

Chairs: Jovan Hadzi-Djokic, Serbia
Norman Zambrano, Chile

1015-1025
POD-6.01

A Retrospective Review of Renal Ablative Therapies for Renal Masses: Clinical Outcomes

Mrinal Dhar, Canada

1025-1035
POD-6.02

A Multicenter, Randomized, Phase III Trial of a Novel, Autologous, Therapeutic Vaccine (Vitespen) vs. Observation as Adjuvant Therapy in Patients at High Risk of Recurrence After Nephrectomy for Renal Cell Carcinoma

Simon Tanguay, Canada

This presentation was supported by an unrestricted educational grant from Antigenics

1035-1045

The Comparison of Efficacy and Side Effects Between M-VAC and GC Chemotherapy in Advanced and Metastatic Urothelial Carcinoma Patients with Good Performance Status

Jae Il Chung, South Korea

1045-1055
POD-6.04

Evaluation of Sorafenib Treatment in Metastatic Renal Cell Carcinoma with Positron Emission Tomography

David Lyrdal, Sweden

1055-1105
POD-6.05

Treatment of Metastatic Renal Cell Carcinoma by Peginterferon Alpha-2b

Sven Lundstam, Sweden

1105-1115
POD-6.06

Robotic Nephrectomy for Treatment of Benign and Malignant Renal Disease

Rajesh Laungani, USA

1115-1125
POD-6.07

Surgical Morbidity Associated with Administration of Targeted Molecular Therapies Prior to Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma

Christopher Wood, USA

1125-1135
POD-6.08

Positive Margin After Nephron Sparing Surgery: Our Experience

Eduard Garcia-Cruz, Spain

1135-1145
POD-6.09

Retroperitoneal Lymph Node Recurrence in Patients with Transitional Cell Carcinoma of Upper Urinary Tract

Sung Joon Hong, South Korea

1145-1155
POD-6.10

Robotic Partial Nephrectomy: A Multi-Institutional Analysis

Craig Rogers, USA

1155-1205
POD-6.11

Computerized Tomography Measurement of Visceral Adiposity Predicts Plasma Adiponectin Levels and Presence of Metastatic Disease in Patients with Clear Cell Renal Cell Carcinoma

Anil Kapoor, Canada

1205-1215
POD-6.12

Progression Free Survival in Patients with Metastatic and Recurrent Renal Cancer Treated with Sorafenib: Single Center Experience

Anil Kapoor, Canada

1215-1225
POD-6.13 **Serum Amyloid Alpha 1:
Potential Marker for Renal Cell
Carcinomas?**

Kerstin Junker, Germany

POD-7 – Bladder Cancer

ROOM: Don Alberto 5

Chair: Petrisor Geavlete, Romania

1015-1025
POD-7.01 **Laparoscopic Radical Cystectomy:
Our Results After 85 Consecutive
Patients**

Octavio Castillo, Chile

1025-1035
POD-7.02 **Neobladder Reconstruction
After Extraperitoneal Ultrasound
Assisted Radical Cystectomy:
A Report on an Easy Procedure**

Edoardo Austoni, Italy

1035-1045
POD-7.03 **Micropapillary Bladder Cancer:
Comparison of Outcomes with Up-
front Cystectomy and Neoadjuvant
Chemotherapy**

Ashish Kamat, USA

1045-1055
POD-7.04 **The Role for Radical
Cystoprostatectomy in Patients with
Clinical T4b Bladder Cancer**

Ashish Kamat, USA

1055-1105
POD-7.05 **The Role of Prostatic Urethral
Biopsy in Counseling Patients
Regarding Orthotopic Neobladder
Reconstruction**

Ashish Kamat, USA

1105-1115
POD-7.07 **Can We Determine the Result of
Repeat Transurethral Resection in
Patients with Newly Diagnosed Non-
muscle Invasive Bladder Cancer?**

Roman Tomaskin, Slovakia

1115-1125
POD-7.08 **Intravesical Mitomycin C Versus
Bacillus Calmette-Guérin for Non-
muscle Invasive Bladder Cancer:
An Individual Patient Data Meta-
Analysis of Randomized Studies**

Per-Uno Malmström, Sweden

1125-1135
POD-7.09 **Combination of Cell Cycle Regulating
Bio-Markers Improves Prognosis
in Patients with Organ Confined
Urothelial Cancer at Radical
Cystectomy**

Arthur Sagalowsky, USA

1135-1145
POD-7.10 **Blocking AKT Pathway Inhibits
X-IAP and Enhances Taxol-induced
Apoptosis of Bladder Cancer**

Chi-Rei Yang, Taiwan

1145-1155
POD-7.11 **The Effect of the Patient's Age on
Bladder Cancer Immunotherapy
Response and Adverse Events:
MCC Experience**

François Charette, Canada

1155-1205
POD-7.12 **Impact of Age on the Ability of
Mycobacterial Cell Wall-DNA Complex
(MCC) to Induce Urinary Biological
Response Markers in Patients with
Non-muscle Invasive Bladder Cancer**

Mario C. Filion, Canada

1205-1215
POD-7.13 **Robotic-Assisted Laparoscopic
Surgery for Invasive Bladder Cancer:
Can the Lymph Node Dissection
Match the Benchmarks of Open
Surgery?**

John Davis, USA

1230-1300 **Lunch Break**

1300-1400 **Report of the ICUD Consultation on Penile Cancer**

ROOM: Doña Inés

 *English-Spanish Translation Provided*

Chair: Antonio Lima Pompeo, Brazil

Subcommittee Chairs: Antonio Cubilla, Paraguay
Vincenzo Ficarra, Italy
Chris Heyns, South Africa
Arturo Mendoza Valdés, Mexico
Suks Minhas, UK
Curtis Pettaway, USA
Mariela Pow-Sang, Peru

1400-1500 **Take-Home Messages**

ROOM: Doña Inés

 *English-Spanish Translation Provided*

Chairs: Richard D. Williams, USA
Simon Tanguay, Canada

1400-1410 **Prostate Cancer**
René Sotelo, Venezuela

1410-1420 **Bladder Cancer**
Petrisor Geavlete, Romania

1420-1430 **Kidney Cancer**
Richard Santucci, USA

1430-1440 **Testis Cancer**
Joel Shienfeld, USA

1440-1450 **Sociedad Chilena de Urología**
Gustavo Salgado, Chile

1450-1500 **GURS**
Allen Morey, USA

0800-1600 **Pediatric Uro-Oncology Update**
This session is concurrent with the SIU Uro-Oncology programme

ROOM: Don Alberto 4

Chairs: Ricardo Zubieta, Chile
Philip Ransley, UK

0800-0830 **Registration**

0830-0835 **Welcome**

Ricardo Zubieta, Chile, and Philip Ransley, UK

0835-0930 **Round Table: Current Status of Uro-Oncology-Past and Future**

Moderator: Carmen Salgado, Chile
Participants: Mauricio Reyes, Chile,
Alejandra Henríquez, Chile
Karen Goset, Chile
Milena Villaroel, Chile

0930-1100 **Wilms' Tumor PED-2.1**

Chair: Philip Ransley, UK

0930-1010 **Late GU Effects of Pediatric Malignancies and Overview of the National Wilms' Tumor Study**
Margarett Shnoravorian, USA

1010-1025 **Update on Biology and Genetics of Urogenital Tumors**
Marcio Malogolowkin, USA

1025-1040 **Long-Term Outcomes for Bilateral Wilms' Tumors**
Pablo Lobos, Argentina

1040-1055 **Laparoscopic Surgery for Wilms' Tumors**
Francisco Denes, Brazil

1100-1130 **Coffee Break**

1130-1300 **Rhabdomyoblastoma
PED-2.2**

Chair: Margaret Shnorhavorian, USA

1130-1210 **Conservative Surgery for
Rhabdomyoblastoma and Long-Term
Outcomes**

Andrew Kirsch, USA

1210-1225 **Is There a Place for
Rhabdomyosarcoma Surgery?**

Antonio Macedo, Brazil

1225-1240 **Treatment Strategies and Results in
Urologic Manifestations of Pediatric
Rhabdomyosarcoma**

Raimund Stein, Germany

1240-1255 **Brachytherapy in Bladder and
Urethral Rhabdomyosarcoma.
Urological Management in the
Chilean Experience**

Renato Gana, Chile

1300-1400 **Lunch**

1400-1500 **Testis Tumors
PED-2.3**

Chair: Ricardo González, USA

1400-1440 **Germinal Cell and Gonadal Tumors in
Intersex Disorders Throughout Life**

Leendert Looijenga, Netherlands

1440-1455 **Testis Tumors**

Margaret Shnorhavorian, USA

1500-1520 **Sarcomas: How Should We Face
Those Tumors That Don't Respond?**

Marcio Malogolowkin, USA

1520-1620 **Free Papers**

Chair: Philip Ransley, UK

PED-08 **Unsuspected Gonadoblastoma:
The Role of Laparoscopic
Gonadectomy in Disorders of
Sexual Differentiation**

Joseph Ortenberg, USA

PED-09 **Treatment of Non-metastatic
Rhabdomyosarcoma of the Prostate
in Childhood and Adolescence:
The Role of Surgery**

Juan Carlos López, Argentina

PED-10 **Phaeochromocytoma in Children:
Is the Laparoscopic Adrenalectomy
Safe?**

Francisco Tibor Dénes, Brazil

1400-1430 **Embryonal Rhabdomyosarcoma of the Urachus Presenting as Acute Abdomen: A Case Report**

Nelly Letelier, Chile

1430-1450 **Testis-Sparing Surgery for Intratesticular Masses Testis Tumors**

José Escala, Chile

1615-1630 **Coffee Break**

1630-1650 **Long-Term Outcome of Reconstructive Surgery**
PED-2.4

Chair: Ricardo Zubieta, Chile

Malignancy Risks with Augmentation in Children

Ricardo González, USA

1700-1800 **Neuroblastoma**
PED-2.5

Chair: Francisco de Badiola, Argentina

1700-1730 **Surgical Treatment of Neuroblastoma: When Should the Urologist Be Involved?**

Raimund Stein, Germany

1730-1800 **Current Role of Chemotherapy**
Marcio Malogolowkin, USA

1800

Take-Home Messages
PED-2.6

Ricardo Zubieta, Chile
Philip Ransley, UK